Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more
Cellectis SA (CLLS) - Total Liabilities
Latest total liabilities as of September 2025: $242.57 Million USD
Based on the latest financial reports, Cellectis SA (CLLS) has total liabilities worth $242.57 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cellectis SA - Total Liabilities Trend (2007–2024)
This chart illustrates how Cellectis SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cellectis SA Competitors by Total Liabilities
The table below lists competitors of Cellectis SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elme Communities
NYSE:ELME
|
USA | $777.68 Million |
|
Nam Tai Property Inc.
PINK:NTPIF
|
USA | $303.19 Million |
|
Taekwang Ind
KO:003240
|
Korea | ₩659.85 Billion |
|
Formosa Laboratories Inc
TW:4746
|
Taiwan | NT$4.99 Billion |
|
HKFoods Oyj A
HE:HKFOODS
|
Finland | €334.10 Million |
|
Mildef Crete
TWO:3213
|
Taiwan | NT$982.97 Million |
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
USA | $282.68 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Cellectis SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis SA (2007–2024)
The table below shows the annual total liabilities of Cellectis SA from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $252.51 Million | +1.18% |
| 2023-12-31 | $249.57 Million | +84.49% |
| 2022-12-31 | $135.28 Million | -7.09% |
| 2021-12-31 | $145.60 Million | -9.35% |
| 2020-12-31 | $160.62 Million | +43.42% |
| 2019-12-31 | $112.00 Million | +121.48% |
| 2018-12-31 | $50.57 Million | +7.64% |
| 2017-12-31 | $46.98 Million | -17.05% |
| 2016-12-31 | $56.63 Million | -33.11% |
| 2015-12-31 | $84.67 Million | -10.83% |
| 2014-12-31 | $94.95 Million | +153.46% |
| 2013-12-31 | $37.46 Million | +12.10% |
| 2012-12-31 | $33.42 Million | -64.77% |
| 2011-12-31 | $94.86 Million | +396.58% |
| 2010-12-31 | $19.10 Million | +5.44% |
| 2009-12-31 | $18.12 Million | +23.92% |
| 2008-12-31 | $14.62 Million | +41.54% |
| 2007-12-31 | $10.33 Million | -- |